Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJeremy S. Abramson, Andrew M. Evens, Tatyana Feldman et al.|Annals of Oncology|2014Cited by 138
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Christopher P. Fox et al.|Clinical Cancer Research|2019Cited by 90
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL RegistryAnthony R. Mato, Jeff P. Sharman, Chadi Nabhan et al.|Clinical Lymphoma Myeloma & Leukemia|2017Cited by 29
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)Anthony R. Mato, Jennifer A. Woyach, Matthew S. Davids et al.|Clinical Cancer Research|2021Cited by 21